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The coxsackievirus and adenovirus receptor (CAR) is a membrane glycoprotein with a cytoplasmic domain, a transmembrane
domain and an extracellular region consisting of two immunoglobulin-like domains, an amino-terminal immunoglobulin variable (IgV)-
related domain (D1), which is distal to the cell surface, and a proximal IgC2 domain (D2). The coxsackievirus and adenovirus
receptor has been shown to exhibit tumour suppression activity in human bladder and prostate cancer cells. In the current paper, we
demonstrate that CAR is a tumour suppressor in glioma cells and that the extracellular D2 domain is not required for this inhibitory
effect. This finding provides a biological basis for the observation that expression of CAR is downregulated in malignant glioma cells.
This suggests that strategies to redirect adenoviruses to achieve CAR-independent infection will be necessary to realise the full
potential of adenoviral vectors for cancer gene therapy.
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The first step in infection by many human adenoviruses, including
the subgroup C serotypes 2 and 5 most commonly used in gene
therapy applications, is the high-affinity binding of the knob
domain of the fibre protein (Henry et al, 1994; Louis et al, 1994) to
the primary cellular receptor, the coxsackievirus and adenovirus
receptor (CAR). The coxsackievirus and adenovirus receptor is a
46kDa class I membrane glycoprotein with a carboxy-terminal
cytoplasmic domain, a transmembrane domain and an extra-
cellular region consisting of two immunoglobulin-like domains, an
amino-terminal immunoglobulin variable (IgV)-related domain
(D1), which is distal to the cell surface, and a proximal IgC2
domain (D2). Although there is evidence for the evolutionary
conservation of CAR, with homologues of the human receptor,
hCAR, present in several mammalian species, including mice
(Tomko et al, 1997; Bergelson et al, 1998), rats, dogs and pigs
(Fechner et al, 1999) as well as in zebrafish (van Raaij et al, 2000),
the normal physiological function of this membrane protein is
unknown.
The identification of CAR as the primary adenovirus receptor
triggered numerous studies demonstrating that primary cancer
cells are frequently refractory to adenoviral infection because of a
paucity of CAR on the cell surface (Dmitriev et al, 1998; Hemmi
et al, 1998; Miller et al, 1998; Blackwell et al, 1999; Li et al, 1999;
Vanderkwaak et al, 1999). More recently, it has been shown that
the expression of CAR in highly tumorigenic CAR-deficient human
prostate and bladder cancer cells leads to a growth-inhibitory
effect (Okegawa et al, 2000, 2001). We have previously reported
that the tumorigenic human U-118 MG glioblastoma cell line is
refractory to adenoviral infection because of a paucity of CAR
although it expresses the av integrins necessary for virus
internalisation (Miller et al, 1998). In the current study, we have
tested the hypothesis that CAR serves as a tumour suppressor in
this cell type. We also sought to determine which structural
domains of CAR are responsible for its tumour-suppressive
activity.
MATERIALS AND METHODS
Construction of plasmids encoding mutant forms of CAR
The 2.4kb BamHI–NotI fragment carrying the hCAR cDNA was
first subcloned from pcDNAI.hCAR (obtained from Robert W
Finberg, Harvard Medical School, Boston, MA, USA) into the
mammalian expression vector pcDNA3 (Invitrogen, Carlsbad, CA,
USA) to give pcDNA3-hCAR. This plasmid was then used as
template for PCR mutagenesis to construct the tailless hCAR
truncation mutant by insertion of a stop codon after the position
corresponding to amino-acid residue 260 (Wang and Bergelson,
1999). This construct therefore contained the extracellular domain,
transmembrane domain and the first two amino acids from the
cytoplasmic domain of hCAR. The hCAR-GPI construct was
generated by overlap extension PCR to fuse the extracellular
domain of hCAR (corresponding to amino-acid residues 1–235) to
the 37 carboxy-terminal amino acids of human decay-accelerating
factor (DAF) (Wang and Bergelson, 1999). The PCR products were
inserted into the BamHI and NotI sites of pcDNA3 to give
pcDNA3-hCAR-tailless and pcDNA3-hCAR-GPI, respectively.
Deletion mutants of hCAR lacking the D1 or D2 extracellular
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ydomains (lacking amino acids 21–144 and 145–233, respectively
(Freimuth et al, 1999)) were constructed by overlap extension
PCR using pcDNA3-hCAR as the template. The PCR products
were inserted into the BamHI and NotI sites of pcDNA3 to
give pcDNA3-hCARDD1 and pcDNA3-hCARDD2, respectively.
The integrity of all constructs was verified by DNA sequencing
using the CEQ2000XL DNA analysis system (Beckman-Coulter,
Fullerton, CA, USA).
Cell culture
CAR-positive 293 cells (Graham et al, 1977) were purchased from
Microbix (Toronto, Ontario, Canada) and CAR-negative human
U-118 MG glioma cells were obtained from the American Type
Culture Collection (Manassas, VA, USA). The cells were propa-
gated at 371C in a 5% CO2 atmosphere in 50:50 mixture of
Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium
(DMEM/F-12), supplemented with 10% (vv
1) fetal calf serum
(FCS), L-glutamine (2mM), penicillin (100Uml
1) and streptomy-
cin (100mgml
1). Stable transfectants were maintained in
400mgml
1 G418. FCS was purchased from Gibco-BRL (Grand
Island, NY, USA), and media and supplements were from
Mediatech (Herndon, VA, USA).
Transfection of U-118 MG cells and selection
of stable clones
U-118 MG cells were transfected with the plasmids encoding hCAR
or the hCAR deletion mutants using Superfect (Qiagen, Valencia,
CA, USA) according to the manufacturer’s protocol. Cells stably
expressing hCAR or the hCAR deletion mutants were selected in
the presence of G418 at a concentration of 400mgml
1.
Flow cytometry Confluent cells were released with Versene and
resuspended in phosphate-buffered saline (PBS; Mediatech)
containing 1% bovine serum albumin (BSA; Boehringer Man-
nheim, Indianapolis, IN, USA) at a concentration of 1–210
6cells
per ml. One hundred microliters of cells (1–210
5) were
incubated with 100ml of anti-hCAR monoclonal antibody RmcB
at a concentration of 10mgml
1 for 1h at 41C with constant
shaking. Cells were then washed with PBS containing 1% BSA and
incubated with 100ml of fluorescein isothiocyanate (FITC)-labelled
rabbit anti-mouse IgG, Fc-specific secondary antibody (Jackson
Immunoresearch Laboratories,West Grove, PA, USA) at a con-
centration of 10mlml
1 for 1h at 41C with constant shaking. Cells
were washed with PBS containing 1% BSA and fixed to a final
volume of 300ml of 1–2% paraformaldehyde. Samples were then
analysed by flow cytometry in the University of Alabama FACS
Core Facility on an FACSCalibur machine using Cell quest FACS
analysis software (Becton-Dickinson, Franklin Lakes, NJ, USA).
Adenoviral vectors
Ad5Luc1 is a first generation, E1-, E3-deleted Ad5 vector, which
expresses firefly luciferase under the control of the cytomegalo-
virus (CMV) immediate-early promoter (Krasnykh et al, 2001).
The recombinant adenoviral vectors were propagated on the
permissive 293 cell line, purified by two rounds of cesium chloride
density centrifugation and plaque titred on 293 cells according to
standard techniques (Anon, 1998).
Adenovirus-mediated reporter gene transfer assays
In experiments to assay adenovirus-mediated luciferase gene
delivery, 70% confluent U-118MG cells or the stable transfectants
in a 24-well tray were infected at a multiplicity of infection (MOI)
of 100 plaque-forming units (PFU) per cell by adding Ad5Luc1
diluted in 100ml DMEM+2% FCS and incubating for 30min at
room temperature. The unbound virus was then aspirated and the
cells were washed with DMEM+2% FCS and incubated in 100ml
DMEM+2% FCS for 1h at 371C. One hundred microlitres of
DMEM+10% FCS were then added and the cells were incubated at
371C for a further 24h to allow luciferase expression. The cells
were then lysed and assayed for luciferase activity using a
luciferase assay system (Promega, Madison, WI, USA) according
to the manufacturer’s protocol.
In vitro soft agar colony-formation assay
U-118 MG cells were transfected with the various hCAR expression
vectors and stable transfectants selected in the presence of
400mgml
1 G418. Monolayers of cells were released with Versene
and dispersed into a suspension of single cells in growth medium.
One thousand cells were resuspended in 2ml of growth medium
containing 0.4% low melting temperature agarose (Sea Plaque;
FMC Products) and 400mgml
1 G418, and were overlaid in
triplicate on 2ml of solidified 0.8% low melting temperature
agarose in growth medium in a 6-well dish. The dishes were
incubated for 18 days at 371C in a 5% CO2 atmosphere. Colonies
larger than 50 cells were then counted. Descriptive statistics (mean
and standard deviation) on colony sizes were calculated. The mean
colony sizes7standard deviations are shown. Statistical analysis
was performed using one-way ANOVA. Po0.05 was considered
statistically significant. All statistical tests were performed with
Statistical Analysis Software (Version 6.12; SAS Institute, Inc.,
Cary, NC, USA).
In vivo tumorigenicity assay
Tumour xenografts were established by subcutaneous injection of
510
6U-118 MG cells or the stably transfected derivatives into the
flank of 8- to 10-week-old female athymic nude mice (nine or 10
mice per group) (nu/nu; Frederick Cancer Center, Frederick, MD,
USA). Bidimensional tumour measurements were taken with
calipers and the tumour volume was calculated using the
simplified formula for a rotational ellipsoid: 0.5lengthwidth
2
(Dethlefsen et al, 1968). Statistical analysis was performed by one-
way ANOVA using SAS. Po0.05 was considered statistically
significant.
RESULTS
We first constructed two previously described truncation mutant
forms of hCAR–tailless hCAR, containing the extracellular
domain, transmembrane domain and the first two amino acids
from the cytoplasmic domain of hCAR, and glycosylphosphatidyl
(GPI)-anchored hCAR, lacking both the transmembrane and
cytoplasmic domains (Figure 1) (Wang and Bergelson, 1999).
The hCAR cDNA was first subcloned into the mammalian
expression vector pcDNA3 to give pcDNA3-hCAR. This plasmid
was then used as template for PCR mutagenesis to construct the
tailless hCAR truncation mutant by insertion of a stop codon after
the position corresponding to amino-acid residue 260 (Wang and
Bergelson, 1999). The CAR-GPI construct was generated by
overlap extension PCR to fuse the extracellular domain of hCAR
(corresponding to amino-acid residues 1–235) to the 37 carboxy-
terminal amino acids of human decay-accelerating factor (DAF)
(Wang and Bergelson, 1999). The PCR products were inserted into
pcDNA3 to give pcDNA3-hCAR-tailless and pcDNA3-hCAR-GPI,
respectively. The integrity of the constructs was verified by DNA
sequencing.
Monolayers of CAR-negative human U-118 MG malignant
glioma cells were stably transfected with pcDNA3-hCAR,
pcDNA3-hCAR-tailless, pcDNA3-hCAR-GPI or with the parental
pcDNA3 plasmid as a control. Individual single-cell clones were
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G418. Clones expressing equivalent levels of hCAR and the
truncation mutants were identified on the basis of their suscept-
ibility to infection by Ad5Luc1 (Krasnykh et al, 2001), an
E1-deleted Ad5 vector which expresses the luciferase reporter
gene under the control of the CMV promoter (data not shown).
Expression of hCAR and the truncation mutants on the surface of
the cells was confirmed by fluorescence-activated cell sorting
(FACS) analysis using anti-hCAR monoclonal antibody RmcB,
which verified that the selected clones represented pure popula-
tions of stably transfected cells (Figure 2).
Tumour xenografts were established by subcutaneous injection
of 510
6U-118 MG cells or the stably transfected derivatives into
the flank of 8- to 10-week-old female athymic nude mice (nine
mice per group). Bidimensional tumour measurements were taken
with calipers and the tumour volume was calculated. The mean
tumour volumes on days 14 and 21 are shown in Figure 3. As
expected, stable transfection of the U-118 MG cells with the
parental pcDNA3 vector did not inhibit the growth of
the subcutaneous tumors (P40.05 on days 14 and 21). However,
the U-118 MG cells stably transfected with hCAR showed a
significant decrease in tumorigenicity relative to the parental cells
(Po0.05 on days 14 and 21, respectively). The U-118 MG cells
stably transfected with hCAR-tailless likewise showed a significant
decrease in tumorigenicity relative to the parental cells (Po0.01 on
day 14; Po0.05 on day 21), whereas no inhibition in tumour
growth was observed with the cells stably transfected with hCAR-
GPI (P40.05 on days 14 and 21). These findings are in accordance
with earlier reports that the extracellular and transmembrane
domains of hCAR, together with the first two amino acids of the
cytoplasmic domain, are required for its biological activity in
suppressing growth in human prostate and bladder cancer cells
(Okegawa et al, 2000, 2001).
We then sought to examine the role of the extracellular domains
of hCAR in the tumour-suppressive activity. Deletion mutants of
hCAR (Figure 1) lacking the D1 or D2 extracellular domains
(lacking amino acids 21–144 and 145–233, respectively (Freimuth
et al, 1999)) were constructed by overlap extension PCR using
pcDNA3-hCAR as the template. The PCR products were subcloned
into pcDNA3 to give pcDNA3-hCARDD1 and pcDNA3-hCARDD2,
respectively. The integrity of the constructs was verified by DNA
sequencing.
We first investigated the ability of the deletion mutants to
function as primary cellular receptors for human adenovirus
serotype 5 (Ad5). Monolayers of U-118 MG malignant glioma cells
were transiently transfected with pcDNA3-hCAR, pcDNA3-
hCARDD1 and pcDNA3-hCARDD2. Forty-eight hours post-trans-
fection, the cells were infected at a multiplicity of infection of 100
plaque-forming units per cell with Ad5Luc1. The cells were
incubated for a further 24h and the luciferase activity was
determined. As shown in Figure 4, the parental U-118 MG cells
were refractory to adenoviral infection, while expression of full-
length CAR rendered the U-118 MG cells susceptible to adenoviral
infection. Luciferase expression in the cells transiently transfected
with pcDNA3-hCARDD1 was not enhanced over the parental cells,
indicating that the hCAR deletion mutant lacking the membrane-
distal extracellular D1 domain was unable to mediate adenoviral
Cytoplasmic
domain
TM domain
hCAR
D1 domain
D2 domain
  hCAR-tailless hCAR-GPI hCAR∆D1 hCAR∆D2
Figure 1 Schematic diagram of hCAR and deletion mutants. The
coxsackievirus and adenovirus receptor comprises an extracellular region, a
transmembrane domain (hatched rectangle) and a cytoplasmic domain
(open rectangle). The extracellular region of wild-type CAR comprises an
amino-terminal IgV-related domain designated D1 (solid oval), which is
distal to the cell surface, and a proximal IgC2 domain designated D2 (open
oval). The hCAR-tailless mutant is truncated after amino acid 260. The
hCAR-GPI mutant consists of the extracellular domain of hCAR
(corresponding to amino-acid residues 1–235) fused to the 37 carboxy-
terminal amino acids of human DAF. The hCARDD1 mutant lacks amino
acids 21–144, while the hCARDD2 mutant lacks amino acids 145–233
(Freimuth et al, 1999).
100 101 102 103 104
FITC
100 101 102 103 104
FITC
U-118 MG U-118 MG-pcDNA3
U-118 MG-hCAR U-118 MG-hCAR-tailless U-118 MG-hCAR-GPI
150
120
90
60
30
0
C
o
u
n
t
s
100 101 102 103 104
FITC
100 101 102 103 104
FITC
100 101 102 103 104
FITC
150
120
90
60
30
0
C
o
u
n
t
s
150
120
90
60
30
0
C
o
u
n
t
s
150
120
90
60
30
0
C
o
u
n
t
s
150
120
90
60
30
0
C
o
u
n
t
s
Figure 2 FACS analysis of stably transfected cells to confirm surface expression of hCAR and deletion mutants. Dark line is anti-hCAR primary
monoclonal antibody RmcB plus FITC-labelled secondary antibody. Light line is FITC-labelled secondary antibody in the absence of primary antibody.
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cells transiently transfected with pcDNA3-hCARDD2, the plasmid
expressing the hCAR deletion mutant lacking the extracellular D2
domain. This indicates that the membrane-displayed D1 domain of
CAR was able to serve as a primary receptor for human adenovirus
serotype 5. This observation is in accordance with previous
studies which have shown that the isolated recombinant CAR D1
domain binds to the adenovirus fibre knob (Freimuth et al,
1999).
U-118 MG cells were then stably transfected with the various
hCAR expression vectors and individual single-cell clones were
isolated and expanded by selection in the presence of 400mgml
1
G418. Real-time quantitative RT–PCR and immunoblot analysis
employing anti-hCAR monoclonal antibodies was performed
in an attempt to choose clones expressing equivalent levels of
hCAR, hCARDD1, and hCARDD2 mRNA and protein. The
specificity of these assays for hCAR was assured by employing
hCAR-positive 293 cells and hCAR-negative U-118 MG cells
as controls. We were able to identify clones expressing approxi-
mately the same amounts of hCAR and hCARDD2, as determined
from the respective mRNA and protein levels (data not shown).
However, in spite of multiple attempts, we were unable to isolate a
clone in which the level of hCARDD1 mRNA or protein was greater
than 10% of the level achievable with hCAR or hCARDD2 (data not
shown).
Tumour xenografts were again established by subcutaneous
injection of 510
6 U-118 MG cells or the stably transfected
derivatives into the flank of 8- to 10-week-old female athymic nude
mice (10 mice per group). The mean tumour volumes on days 14
and 21 are shown in Figure 5. The U-118 MG cells stably
transfected with hCAR showed a significant decrease in tumori-
genicity relative to the parental cells (Po0.05 on day 14; Po0.01
on day 21). Expression of hCARDD2 also resulted in a significant
inhibitory effect on the growth of the U-118 MG tumours (Po0.05
on days 14 and 21, respectively). Moreover, the size of the U-118
MG-hCARDD2 tumours was not significantly different from that of
the U-118 MG-hCAR tumours (P40.05 on days 14 and 21,
respectively). These results therefore indicate that the expression
of hCAR or hCARDD2 inhibits the tumorigenicity of U-118 MG
glioma cells in vivo. In contrast, expression of hCARDD1 did not
have a tumour-suppressive effect: the U-118 MG-hCARDD1
tumours were not significantly different in size from the parental
U-118 MG tumours (P40.05 on days 14 and 21), although this
could have been due to the low level of expression of hCARDD1 in
the stably transfected U-118 MG cells.
In order to rule out the possibility of the tumour-suppressive
activity observed in vivo being due to a clonal effect, U-118 MG
cells were again transfected with pcDNA3-hCAR, pcDNA3-
hCARDD1 or pcDNA3-hCARDD2 and stable transfectants selected
in the presence of 400mgml
1 G418. The tumorigenicity of the
parental U118-MG cells and pooled clones of the derivative cell
lines was determined in vitro in a soft agar colony-formation assay.
Monolayers of cells were released with Versene and dispersed into
a suspension of single cells. One thousand cells were resuspended
in 2ml of growth medium containing 0.4% low melting
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Figure 3 In vivo tumorigenicity assay. Tumour xenografts were
established by subcutaneous injection of 510
6U-118 MG cells or the
stably transfected derivatives into the flank of 8- to 10-week-old female
athymic nu/nu nude mice (nine mice per group). Bidimensional tumour
measurements were taken with calipers and the tumour volume was
calculated using the simplified formula for a rotational ellipsoid:
0.5lengthwidth
2 (Dethlefsen et al, 1968). The mean tumour
volumes7standard deviations on days 14 (A) and 21 (B) are shown.
Statistical significance was achieved if Po0.05, based upon a one-way
ANOVA.
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Figure 4 Adenovirus-mediated gene transfer to U-118 MG and
derivative cells. Monolayers of CAR-negative human U-118 MG malignant
glioma cells were transiently transfected with pcDNA3-hCAR, pcDNA3-
hCARDD1 and pcDNA3-hCARDD2. Forty-eight hours post-transfection,
the cells were infected at a multiplicity of infection of 100p.f.u. per cell with
Ad5Luc1. After incubation for 1h at 371C, the vector was aspirated and
the cells incubated at 371C for 24h. The cells were then lysed and assayed
for luciferase activity, which is expressed as relative light units. Data are
reported as the means7standard deviations of triplicate determinations
from a representative of three independent experiments. Po0.05 was
considered statistically significant.
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1 G418 in the case of the
transfected cells, and were overlaid in triplicate on 2ml of
solidified 0.8% low melting temperature agarose in growth
medium in a six-well dish. The dishes were incubated for 18 days
at 371C in a 5% CO2 atmosphere. Colonies containing more than
50 cells were then counted.
As shown in Figure 6, expression of hCAR by U-118 MG
cells caused a significant reduction in the number of colonies
formed by the glioma cells in this assay (Po0.05). The
mean number of U-118 MG colonies was 149732, while the mean
number of U-118 MG-hCAR colonies was 88714. The
mean number of U-118 MG-hCARDD2 colonies was 7875,
which was significantly less than the number of colonies
formed by the parental U-118 MG cells (Po0.05), but not
significantly different from the number of U-118 MG-hCAR
colonies (P40.05). The mean number of U-118 MG-hCARDD1
colonies was 223722, which was significantly greater than the
numbers of both U-118 MG-hCAR and U-118 MG-hCARDD2
colonies (Po0.001 in each case). The results of this soft agar
colony-formation assay therefore indicate that expression of both
hCAR and hCARDD2 results in a tumour-inhibitory effect in vitro,
while expression of hCARDD1 does not suppress the growth of the
glioma cells in vitro.
DISCUSSION
Previous reports have shown that the extracellular and transmem-
brane domains of hCAR, together with the first two amino acids of
the cytoplasmic domain, are required for its biological activity in
suppressing growth in human prostate and bladder cancer cells
(Okegawa et al, 2000, 2001). We have extended those studies by
showing that the extracellular D2 domain of hCAR is not required
for CAR to function as a tumour suppressor.
Our findings demonstrate that CAR serves as a tumour
suppressor in glioma cells both in vitro and in vivo. This provides
a physiological explanation for the downregulation of CAR
observed in malignant glioma cells (Miller et al, 1998), although
the biological trigger underlying this step in the pathway of
malignant transformation remains to be elucidated. Downregula-
tion of CAR has similarly been observed in other tumour types,
including ovarian cancer (Dmitriev et al, 1998), melanoma
(Hemmi et al, 1998) and head and neck cancer (Dmitriev et al,
1998; Hemmi et al, 1998; Li et al, 1999). The level of expression of
CAR mRNA in bladder cancer specimens from human patients has
been shown to correlate inversely with the aggressiveness of the
tumour: invasive bladder cancer specimens had significantly
reduced CAR mRNA levels compared with superficial bladder
cancer specimens (Okegawa et al, 2001). Similarly, when compared
with normal prostate, CAR expression is decreased in prostate
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Figure 5 In vivo tumorigenicity assay. Tumour xenografts were
established by subcutaneous injection of 510
6 U-118 MG cells or the
stably transfected derivatives into the flank of 8- to 10-week-old female
athymic nu/nu nude mice (10 mice per group). Bidimensional tumour
measurements were taken with calipers and the tumour volume was
calculated using the simplified formula for a rotational ellipsoid:
0.5lengthwidth
2 (Dethlefsen et al, 1968). The mean tumour
volumes7standard deviations on days 14 (A) and 21 (B) are shown.
Statistical analysis was performed by one-way ANOVA. Po0.05 was
considered statistically significant.
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Figure 6 In vitro soft agar colony-formation assay. U-118 MG cells were
transfected with the various hCAR expression vectors and stable
transfectants selected in the presence of 400mgml
1 G418. Monolayers
of cells were released with Versene and dispersed into a suspension of
single cells in growth medium. One thousand cells were resuspended in
2ml of growth medium containing 0.4% low melting temperature agarose
(and 400mgml
1 G418 in the case of the transfectants), and were overlaid
in triplicate on 2ml of solidified 0.8% low melting temperature agarose in
growth medium in a 6-well dish. The dishes were incubated for 18 days at
371C in a 5% CO2 atmosphere. Colonies larger than 50 cells were then
counted. The mean colony sizes7standard deviations are shown. Statistical
analysis was performed by one-way ANOVA. Po0.05 was considered
statistically significant.
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Conversely, metastatic prostate specimens express CAR (Rauen
et al, 2002). These results suggest that strategies to redirect
adenoviruses to achieve CAR-independent infection will be
necessary to realise the full potential of adenoviral vectors for
gene therapy of primary tumours in the clinical setting (Barnett
et al, 2002).
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